N-Myc Proto-Oncogene Protein
"N-Myc Proto-Oncogene Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A basic helix-loop-helix leucine zipper (bHLHZ) transcription factor and proto-oncogene protein that functions in cell growth and proliferation. In mammals, it is highly expressed in the brain during embryogenesis and is essential for brain development; it is not expressed in adult tissues. Amplification or overexpression of N-Myc occurs in at least 20% of tumors and is associated with a poor prognosis in cases of NEUROBLASTOMA; ALVEOLAR RHABDOMYOSARCOMA; SMALL CELL LUNG CARCINOMA; and neuroendocrine prostate cancer.
| Descriptor ID |
D000071447
|
| MeSH Number(s) |
D12.776.260.103.500.625 D12.776.260.108.092.625 D12.776.624.664.700.158 D12.776.930.125.500.563 D12.776.930.127.092.625
|
| Concept/Terms |
N-Myc Proto-Oncogene Protein- N-Myc Proto-Oncogene Protein
- N Myc Proto Oncogene Protein
- Proto-Oncogene Protein, N-Myc
- BHLHE37 Protein
- NMYC Protein
- Class E Basic Helix-Loop-Helix Protein 37
- Class E Basic Helix Loop Helix Protein 37
- N-Myc Protein
- N Myc Protein
- MYCN Protein
|
Below are MeSH descriptors whose meaning is more general than "N-Myc Proto-Oncogene Protein".
Below are MeSH descriptors whose meaning is more specific than "N-Myc Proto-Oncogene Protein".
This graph shows the total number of publications written about "N-Myc Proto-Oncogene Protein" by people in this website by year, and whether "N-Myc Proto-Oncogene Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "N-Myc Proto-Oncogene Protein" by people in Profiles.
-
A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma. Cancer Res. 2019 Dec 15; 79(24):6166-6177.
-
State of the art in immunotherapy of neuroblastoma. Immunotherapy. 2019 06; 11(9):831-850.
-
A Novel MYCN Variant Associated with Intellectual Disability Regulates Neuronal Development. Neurosci Bull. 2018 10; 34(5):854-858.
-
MYCN contributes to the malignant characteristics of erythroleukemia through EZH2-mediated epigenetic repression of p21. Cell Death Dis. 2017 10 12; 8(10):e3126.
-
PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. Clin Cancer Res. 2017 Aug 01; 23(15):4462-4472.
-
Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res. 2012 Feb 01; 18(3):796-807.